Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Other Events
18 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
UPLOAD
Letter from SEC
28 Dec 23
CORRESP
Correspondence with SEC
12 Dec 23
8-K
Cyclerion Appoints Regina Graul, Ph.D., as President
4 Dec 23
8-K
Cyclerion Strengthens Board of Directors with Experienced Company Builder
1 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
8-K
Departure of Directors or Certain Officers
24 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
23 Oct 23
S-8
Registration of securities for employees
28 Jul 23
10-Q
2023 Q2
Quarterly report
28 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 Jul 23
8-K
Other Events
12 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
DEFM14A
Proxy related to merger
20 Jun 23
PREM14A
Preliminary proxy related to merger
9 Jun 23
8-K
Other Events
1 Jun 23
D
$5.00 mm in equity, sold $5.00 mm, 1 investor
25 May 23
8-K
Unregistered Sales of Equity Securities
25 May 23
8-K
Cyclerion Announces Reverse Stock Split
15 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
DEFA14A
Additional proxy soliciting materials
11 May 23
8-K
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
11 May 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
3 Apr 23
8-K
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
3 Apr 23
PRE 14A
Preliminary proxy
22 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
22 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 22
8-K
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
22 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
6 Oct 22
8-K
Departure of Directors or Certain Officers
30 Sep 22
S-8
Registration of securities for employees
10 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
9 Aug 22
Latest ownership filings
3
RHONDA M. CHICKO
11 Mar 24
SC 13G/A
TYNDALL CAPITAL PARTNERS L P
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Peter M Hecht
26 Jan 24
4
Regina Margaret Graul
26 Jan 24
SC 13G/A
Slate Path Capital LP
22 Jan 24
3
Dina Katabi
11 Dec 23
3
Michael J Higgins
7 Dec 23
3/A
Regina Margaret Graul
7 Dec 23
SC 13D/A
Hecht Peter M
5 Dec 23
3
Regina Margaret Graul
4 Dec 23
4
TERRANCE MCGUIRE
4 Dec 23
4
Peter M Hecht
4 Dec 23
4
ERROL B DESOUZA
4 Dec 23
4
Steven Hyman
4 Dec 23
SC 13G
TYNDALL CAPITAL PARTNERS L P
5 Sep 23
4
TERRANCE MCGUIRE
11 Aug 23
SC 13D/A
Hecht Peter M
23 May 23
4
Peter M Hecht
22 May 23
SC 13D/A
Hecht Peter M
12 May 23
SC 13D/A
Hecht Peter M
3 Apr 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G
Slate Path Capital LP
13 Jan 23
SC 13D/A
Hecht Peter M
21 Nov 22
SC 13D
Slate Path Capital LP
21 Oct 22
4/A
Steven Hyman
27 Jul 22
4
Steven Hyman
26 Jul 22
3
Steven Hyman
26 Jul 22
4
TERRANCE MCGUIRE
16 Jun 22
4
Michael Mendelsohn
16 Jun 22
4
Marsha Fanucci
16 Jun 22
4
Stephanie Lovell
16 Jun 22
4
GEORGE H CONRADES
16 Jun 22
4
Ole Isacson
16 Jun 22
4
ERROL B DESOUZA
16 Jun 22
SC 13G/A
Slate Path Capital LP
11 Feb 22
SC 13G/A
Artal International S.C.A.
11 Feb 22
SC 13G/A
MFN Partners, LP
9 Feb 22
SC 13G/A
FMR LLC
9 Feb 22